Cho Benjamin B, Kelting Sarah M, Gru Alejandro A, LeGallo Robin D, Pramoonjago Patcharin, Goldin Teresa A, Heitz Christopher T, Aguilera Nadine S
Department of Pathology, University of Virginia Health System, Charlottesville, VA.
Department of Pathology, University of Virginia Health System, Charlottesville, VA.
Ann Diagn Pathol. 2017 Feb;26:10-15. doi: 10.1016/j.anndiagpath.2016.10.003. Epub 2016 Oct 8.
Cyclin D1 protein expression in lymphocytes is classically associated with mantle cell lymphoma. Although increasingly recognized in other lymphoproliferative disorders, cyclin D1 expression and CCND1 gene abnormalities have not been well studied in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Using a double stain for CD20/cyclin D1, we quantified cyclin D1 expression in 10 cases of NLPHL and correlated those findings with SOX11 expression, CCND1 gene abnormalities, and clinical data. For comparison, we examined 5 cases of T cell-/histiocyte-rich large B-cell lymphoma (THRLBCL). All cases of NLPHL stained for cyclin D1 showed at least rare positivity in lymphocyte-predominant (LP) cells. In 4 cases, at least 20% of LP cells were positive for CD20/cyclin D1. Neither SOX11 expression nor CCND1 gene rearrangement was found in any of the cases, but fluorescence in situ hybridization showed a proportion of the large cells with 3 to 4 copies of nonfused IGH and CCND1 signals or 3 intact CCND1 break-apart signals. Further study with CCND1/CEP11 showed polysomy in 6 of 9 cases with cyclin D1 expression and 5 of 16 NLPHL not examined for cyclin D1. Two of 5 cases of THRLBCL showed rare positive staining for CD20/cyclin D1; 1 case showed polysomy with CCND1/CEP11. Results show that cyclin D1 may be expressed in LP cells without SOX11 expression or CCND1 translocation. Polysomy with increased copies of CCND1 may account for cyclin D1 expression in some cases. Cyclin D1 expression is not useful for distinguishing NLPHL from THRLBCL and has no apparent clinical significance in NLPHL.
淋巴细胞中的细胞周期蛋白D1蛋白表达传统上与套细胞淋巴瘤相关。尽管在其他淋巴增殖性疾病中越来越多地被认识到,但细胞周期蛋白D1表达和CCND1基因异常在结节性淋巴细胞为主型霍奇金淋巴瘤(NLPHL)中尚未得到充分研究。我们使用CD20/细胞周期蛋白D1双重染色,对10例NLPHL中的细胞周期蛋白D1表达进行了定量,并将这些结果与SOX11表达、CCND1基因异常及临床数据相关联。为作比较,我们检查了5例富于T细胞/组织细胞的大B细胞淋巴瘤(THRLBCL)。所有NLPHL病例中细胞周期蛋白D1染色显示,淋巴细胞为主(LP)细胞至少有罕见的阳性。4例中,至少20%的LP细胞CD20/细胞周期蛋白D1呈阳性。所有病例均未发现SOX11表达或CCND1基因重排,但荧光原位杂交显示部分大细胞有3至4个未融合的IGH和CCND1信号拷贝或3个完整的CCND1分离信号。使用CCND1/CEP11的进一步研究显示:在9例有细胞周期蛋白D1表达的病例中,6例有多体性;在16例未检测细胞周期蛋白D1的NLPHL中,5例有多体性。5例THRLBCL中有2例CD20/细胞周期蛋白D1呈罕见阳性染色;1例CCND1/CEP11有多体性。结果显示,细胞周期蛋白D1可能在无SOX11表达或CCND1易位的LP细胞中表达。CCND1拷贝数增加的多体性可能在某些情况下解释了细胞周期蛋白D1的表达。细胞周期蛋白D1表达对区分NLPHL与THRLBCL无用,且在NLPHL中无明显临床意义。